Dr. Safferstein previously served as Vice President, Business Development, Omrix Biopharmaceuticals, a commercial-stage company that develops and markets biosurgical and passive immunotherapy products. Prior to joining Omrix, he was Executive Vice President, Corporate Development for TransPharma Medical, a privately-held medical device company. From 2001 to 2005, Dr. Safferstein was Vice President, Business Development for Acorda Therapeutics, a CNS drug development and marketing company. Prior to joining Acorda Therapeutics, Dr. Safferstein served in various business development and marketing positions with Bristol-Myers Squibb. From 1991-1997, he was Director, Technology Transfer at the National Heart, Lung and Blood Institute and Cooperative Venture Manager for the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Dr. Safferstein was an NIH Post-Doctoral Fellow and Fellow of the Multiple Sclerosis Society. He received a B.A. in Biochemistry from Rutgers University, a Ph.D. in Human Anatomy and Neurobiology from the University of Louisville, a J.D. from the American University, Washington College of Law and an M.B.A. from Columbia University.
Dr. Hefti brings nearly 20 years experience in the pharmaceutical industry and over a decade experience in academia. He led the drug development efforts at Rinat Neuroscience Corporation as Executive Vice President of Drug Development for three years. During his tenure, three antibody drug candidates advanced from the discovery stage to preclinical and clinical development and the success of these programs led to the acquisition of Rinat Neuroscience by Pfizer in 2006. Previously, Dr. Hefti was Senior Vice President of Neuroscience Research at Merck & Co., where he coordinated the company's neuroscience research worldwide, serving as site head for the neuroscience research centers in the U.K. and U.S. While working with Merck, small molecule drug candidates covering six drug targets in the neuroscience area were taken into development. Dr. Hefti was also Director of the Neuroscience Research Department at Genentech and previously spent more than a decade in academia as a Professor at the University of Southern California and Associate Professor at the University of Miami, where he carried out seminal research on therapeutic applications of neurotrophic factors. He has published over 250 papers on neurotrophic factors and topics in neuropharmacology, and a recent textbook "Drug Discovery for Nervous System Diseases" (John Wiley & Sons). Dr. Hefti received a Ph.D. from the University of Zurich and did his post- doctoral research at the Massachusetts Institute of Technology and the Max Planck Institute in Munich.
Cynthia A. Lemere, Ph.D. Associate Professor of Neurology at Harvard Medical School and an Associate Neuroscientist at Brigham & Women’s Hospital in the Center for Neurologic Diseases (CND). She is a world leader in the field of Alzheimer's disease (AD) research for more than sixteen years. Dr. Lemere received her B.A. from Mount Holyoke College, her M.S. in Neurobiology from State University of New York at Albany, and her Ph.D. in Pathology from Boston University School of Medicine in the laboratory of Dr. Dennis Selkoe. In 1997, she became an Assistant Professor of Neurology at Harvard Medical School and was promoted to Associate Professor in 2004. She is a member of the Scientific Advisory Board for AlzForum. Her current research focuses on the basic mechanisms of AD and protein-based therapeutics.
Dr. LeVine is an Associate Professor at the Department of Molecular and Cellular Biochemistry, Center on Aging at the University of Kentucky College of Medicine. He is a world leader in the biochemistry of amyloid beta protein and drug discovery efforts directed against this target. He received his B.S. in Physiological Chemistry in 1971 from Cornell University, and Ph.D. in Physiological Chemistry in 1975 from Johns Hopkins University School of Medicine. Following his postdoctoral training at the Wellcome Research Laboratories, Dr. LeVine had a 28 year career of research and drug discovery in the pharmaceutical industry, holding scientific leadership positions at Burroughs-Wellcome, Glaxo, Parke-Davis, and Pfizer. Dr. LeVine’s current research focuses on mechanisms of Alzheimer’s amyloid peptide assembly into oligomers and fibrils, as well as drug discovery efforts to discover inhibitors of polymerization of the amyloid peptide with viable drug properties from in vitro screening through animal models up to the pre-Phase I clinical trial stage.